NO20053101L - Kimaere og humaniserte antistoffer motalfa-5beta-1 integrin som modulerer angiogenese. - Google Patents
Kimaere og humaniserte antistoffer motalfa-5beta-1 integrin som modulerer angiogenese.Info
- Publication number
- NO20053101L NO20053101L NO20053101A NO20053101A NO20053101L NO 20053101 L NO20053101 L NO 20053101L NO 20053101 A NO20053101 A NO 20053101A NO 20053101 A NO20053101 A NO 20053101A NO 20053101 L NO20053101 L NO 20053101L
- Authority
- NO
- Norway
- Prior art keywords
- integrin
- chimeric
- humanized antibodies
- motalfa
- 5beta
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Den foreliggende oppfinnelse tilveiebringer kimære og humaniserte antistoffer som spesifikt gjenkjenner oc5pi integrin, og fremgangsmåter for anvendelse av antistoffene for å redusere eller inhibere angiogenese i et vev. Det er også tilveiebragt fremgangsmåter for å bestemme terapeutisk aksepterbare doser av antistoffene og farmasøytiske sammensetninger som inkluderer de samme.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42974302P | 2002-11-26 | 2002-11-26 | |
PCT/US2003/038172 WO2004056308A2 (en) | 2002-11-26 | 2003-11-26 | CHIMERIC AND HUMANIZED ANTIBODIES TO α5β1 INTEGRIN THAT MODULATE ANGIOGENESIS |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20053101D0 NO20053101D0 (no) | 2005-06-24 |
NO20053101L true NO20053101L (no) | 2005-08-26 |
Family
ID=32681936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20053101A NO20053101L (no) | 2002-11-26 | 2005-06-24 | Kimaere og humaniserte antistoffer motalfa-5beta-1 integrin som modulerer angiogenese. |
Country Status (14)
Country | Link |
---|---|
EP (2) | EP1575516B1 (no) |
JP (2) | JP4741242B2 (no) |
KR (2) | KR20050089151A (no) |
CN (1) | CN100369930C (no) |
AU (1) | AU2003298783B2 (no) |
BR (1) | BR0316670A (no) |
CA (1) | CA2507099C (no) |
ES (1) | ES2387985T3 (no) |
MX (1) | MXPA05005558A (no) |
NO (1) | NO20053101L (no) |
NZ (1) | NZ540562A (no) |
RU (1) | RU2346701C2 (no) |
WO (1) | WO2004056308A2 (no) |
ZA (1) | ZA200505114B (no) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA011853B1 (ru) | 2002-03-13 | 2009-06-30 | Байоджен Айдек Ма Инк. | АНТИТЕЛА ПРОТИВ αβ |
US7276589B2 (en) | 2002-11-26 | 2007-10-02 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
KR20070009637A (ko) | 2004-03-24 | 2007-01-18 | 피디엘 바이오파르마 인코포레이티드 | 암 세포 증식을 억제하는 항α5β1 항체의 용도 |
US20060008415A1 (en) * | 2004-06-25 | 2006-01-12 | Protein Design Labs, Inc. | Stable liquid and lyophilized formulation of proteins |
CN102875681A (zh) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
ZA200807754B (en) * | 2006-03-21 | 2009-12-30 | Genentech Inc | Combinatorial therapy involving alpha5beta1 antagonists |
ES2544957T3 (es) * | 2006-03-21 | 2015-09-07 | Genentech, Inc. | Terapia combinada que implica antagonistas alfa5beta1 |
EP2032605A2 (en) * | 2006-05-24 | 2009-03-11 | Bayer Schering Pharma Aktiengesellschaft | HIGH AFFINITY HUMAN AND HUMANIZED ANTI-alpha5ß1 INTEGRIN FUNCTION BLOCKING ANTIBODIES WITH REDUCED IMMUNOGENICITY |
WO2008008315A2 (en) | 2006-07-10 | 2008-01-17 | Biogen Idec Ma Inc. | Compositions and methods for inhibiting growth of smad4-deficient cancers |
WO2009010290A2 (en) * | 2007-07-17 | 2009-01-22 | Merck Patent Gmbh | Engineered anti-alpha v- integrin hybrid antibodies |
CA2694644A1 (en) * | 2007-07-27 | 2009-02-05 | Vanitha Ramakrishnan | Pharmaceutical combinations |
CA2698609A1 (en) * | 2007-09-26 | 2009-04-02 | Genentech, Inc. | Novel antibodies |
BRPI0906387A2 (pt) | 2008-02-05 | 2015-07-07 | Bristol Myers Squibb Co | Anticorpos alfa 5 - beta 1 e seus usos |
KR101054725B1 (ko) * | 2008-07-31 | 2011-08-05 | 재단법인서울대학교산학협력재단 | 세포외기질 성분을 함유하는 노화조절용 조성물 및 이를이용한 노화세포의 노화조절방법 |
US20120114667A1 (en) | 2008-12-23 | 2012-05-10 | Medimmune Limited | TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF |
CA2748161A1 (en) * | 2008-12-23 | 2010-07-01 | Astrazeneca Ab | Targeted binding agents directed to .alpha.5.beta.1 and uses thereof |
US8679492B2 (en) * | 2009-02-23 | 2014-03-25 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to CD19 and their uses |
CA2753988C (en) | 2009-03-25 | 2017-04-25 | Genentech, Inc. | Novel anti-.alpha.5.beta. integrin antibodies and uses thereof |
CN101638429B (zh) * | 2009-08-28 | 2012-01-25 | 南方医科大学 | 一种特异性识别细胞表面整合素α3β1的小分子肽 |
PT3272764T (pt) * | 2009-12-18 | 2024-04-24 | Novartis Ag | Método para cromatografia de afinidade |
JP5972176B2 (ja) | 2010-02-23 | 2016-08-17 | サノフイ | 抗アルファ2インテグリン抗体及びそれらの使用 |
PT2672994T (pt) | 2011-02-11 | 2018-10-22 | Merck Patent Gmbh | Anticorpo anti-integrina alfa-v para o tratamento do cancro da próstata |
WO2013150043A1 (en) * | 2012-04-05 | 2013-10-10 | F. Hoffmann-La Roche Ag | Bispecific antibodies against human tweak and human il17 and uses thereof |
CN104994874B (zh) * | 2012-12-26 | 2017-04-12 | 安科协同公司 | 抗整联蛋白β1抗体组合物及其使用方法 |
US10035860B2 (en) | 2013-03-15 | 2018-07-31 | Biogen Ma Inc. | Anti-alpha V beta 6 antibodies and uses thereof |
WO2014144466A1 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
WO2018226991A1 (en) | 2017-06-07 | 2018-12-13 | Shifamed Holdings, Llc | Intravascular fluid movement devices, systems, and methods of use |
CN111556763B (zh) | 2017-11-13 | 2023-09-01 | 施菲姆德控股有限责任公司 | 血管内流体运动装置、系统 |
EP4085965A1 (en) | 2018-02-01 | 2022-11-09 | Shifamed Holdings, LLC | Intravascular blood pumps and methods of use and manufacture |
US11964145B2 (en) | 2019-07-12 | 2024-04-23 | Shifamed Holdings, Llc | Intravascular blood pumps and methods of manufacture and use |
US11654275B2 (en) | 2019-07-22 | 2023-05-23 | Shifamed Holdings, Llc | Intravascular blood pumps with struts and methods of use and manufacture |
EP4034192A4 (en) | 2019-09-25 | 2023-11-29 | Shifamed Holdings, LLC | INTRAVASCULAR BLOOD PUMP SYSTEMS AND METHODS OF USE AND CONTROL THEREOF |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4704366A (en) * | 1984-06-22 | 1987-11-03 | Bio-Rad Laboratories, Inc. | Process for binding IgG to protein A |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4801687A (en) * | 1986-10-27 | 1989-01-31 | Bioprobe International, Inc. | Monoclonal antibody purification process using protein A |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
ES2204890T3 (es) | 1991-03-06 | 2004-05-01 | Merck Patent Gmbh | Anticuerpos monoclonales humanizados. |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
KR100252547B1 (ko) | 1991-09-05 | 2000-09-01 | 프레드 마리얀스키 | 폴리-또는 올리고누클레오티드의 세포로의 표적화된 전달 |
CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
GB9125979D0 (en) | 1991-12-06 | 1992-02-05 | Wellcome Found | Antibody |
ATE171472T1 (de) | 1992-02-19 | 1998-10-15 | Schering Corp | Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4 |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
JPH10501681A (ja) | 1994-02-22 | 1998-02-17 | ダナ−ファーバー キャンサー インスティチュート | 核酸送達システムならびにその合成および使用方法 |
US5705154A (en) | 1995-03-08 | 1998-01-06 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
US5961955A (en) | 1997-06-03 | 1999-10-05 | Coulter Pharmaceutical, Inc. | Radioprotectant for peptides labeled with radioisotope |
EP1075277B2 (en) * | 1998-05-08 | 2012-10-31 | The Regents of the University of California | Methods for detecting and inhibiting angiogenesis |
US6852318B1 (en) * | 1998-05-08 | 2005-02-08 | The Regents Of The University Of California | Methods for detecting and inhibiting angiogenesis |
US7285268B2 (en) * | 2002-11-26 | 2007-10-23 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
US9111624B2 (en) | 2013-03-22 | 2015-08-18 | Katsuyuki Fujita | Semiconductor memory device |
-
2003
- 2003-11-26 CN CNB2003801091807A patent/CN100369930C/zh not_active Expired - Lifetime
- 2003-11-26 WO PCT/US2003/038172 patent/WO2004056308A2/en active Application Filing
- 2003-11-26 EP EP03796541A patent/EP1575516B1/en not_active Expired - Lifetime
- 2003-11-26 AU AU2003298783A patent/AU2003298783B2/en not_active Expired
- 2003-11-26 KR KR1020057009577A patent/KR20050089151A/ko active IP Right Grant
- 2003-11-26 RU RU2005120019/15A patent/RU2346701C2/ru active
- 2003-11-26 CA CA2507099A patent/CA2507099C/en not_active Expired - Lifetime
- 2003-11-26 ES ES03796541T patent/ES2387985T3/es not_active Expired - Lifetime
- 2003-11-26 EP EP10012456A patent/EP2351583A1/en not_active Withdrawn
- 2003-11-26 NZ NZ540562A patent/NZ540562A/en not_active IP Right Cessation
- 2003-11-26 KR KR1020117029575A patent/KR20110140143A/ko active IP Right Grant
- 2003-11-26 BR BR0316670-8A patent/BR0316670A/pt not_active IP Right Cessation
- 2003-11-26 JP JP2004562249A patent/JP4741242B2/ja not_active Expired - Lifetime
- 2003-11-26 MX MXPA05005558A patent/MXPA05005558A/es active IP Right Grant
-
2005
- 2005-06-23 ZA ZA200505114A patent/ZA200505114B/en unknown
- 2005-06-24 NO NO20053101A patent/NO20053101L/no not_active Application Discontinuation
-
2011
- 2011-01-06 JP JP2011000939A patent/JP2011120593A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP4741242B2 (ja) | 2011-08-03 |
EP2351583A1 (en) | 2011-08-03 |
JP2006516098A (ja) | 2006-06-22 |
AU2003298783B2 (en) | 2010-11-04 |
BR0316670A (pt) | 2005-10-11 |
AU2003298783A1 (en) | 2004-07-14 |
KR20110140143A (ko) | 2011-12-30 |
EP1575516A4 (en) | 2007-09-26 |
NZ540562A (en) | 2008-04-30 |
RU2346701C2 (ru) | 2009-02-20 |
CN1753911A (zh) | 2006-03-29 |
RU2005120019A (ru) | 2006-01-20 |
NO20053101D0 (no) | 2005-06-24 |
EP1575516B1 (en) | 2012-05-30 |
JP2011120593A (ja) | 2011-06-23 |
EP1575516A2 (en) | 2005-09-21 |
CA2507099C (en) | 2013-09-24 |
KR20050089151A (ko) | 2005-09-07 |
MXPA05005558A (es) | 2005-07-26 |
ZA200505114B (en) | 2007-03-28 |
WO2004056308A3 (en) | 2005-09-01 |
CA2507099A1 (en) | 2004-07-08 |
CN100369930C (zh) | 2008-02-20 |
ES2387985T3 (es) | 2012-10-05 |
WO2004056308A2 (en) | 2004-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20053101L (no) | Kimaere og humaniserte antistoffer motalfa-5beta-1 integrin som modulerer angiogenese. | |
NO20081124L (no) | Anti-CD 3 antistoff-formuleringer | |
WO2003034903A3 (en) | Psma antibodies and protein multimers | |
GEP20084484B (en) | Antibodies to insulin-like growth factor i receptor | |
MX337423B (es) | Antagonistas anti-beta7 humanizados y usos para los mismos. | |
CY1111622T1 (el) | Ανθρωποποιημενοι ανταγωνιστες anti-cmet | |
UA90457C2 (ru) | Человеческое моноклональное антитело, которое специфически связывается с м-csf человека и блокирует связывание м-csf с с-fms | |
PE20100251A1 (es) | Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina | |
MY169272A (en) | Her2 antibody composition | |
NO20054351L (no) | Monoklonalt antistoff og hybridom som produserer dette | |
NO20030374D0 (no) | Syklopentanoindoler, preparater som inneholder slike forbindelser og behandlingsfremgangsmåter | |
NO20083895L (no) | Anti-IGF-1R human monoklonalantibody formulering | |
IS6750A (is) | Samrunnin heterósýklísk súkkínímíð efnasambönd oghliðstæður þeirra, stillar fyrir starfsemi kjarnahormónaviðtaka | |
NO20063569L (no) | M-CSF-spesifikt monoklonalt antistoff og anvendelse derav | |
CY1110033T1 (el) | Τεχνητα ανθρωπινα θεραπευτικα αντισωματα εναντια σε ισομορφες cd45 | |
DE60138867D1 (de) | Medikament zum Schutz gegen thrombotische Krankheiten | |
WO2005000194A3 (en) | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same | |
ITTO20020340A1 (it) | Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato. | |
ATE444310T1 (de) | Antiidiotypische antikörper die hiv-1 neutralisierende antikörper induzieren | |
SI1461360T1 (sl) | Konjugati, ki obsegajo protitelo, specifično za domeno ED-B fibronektina, in njihova uporaba za detekcijo in zdravljenje tumorjev | |
CY1116949T1 (el) | M-csf-ειδικο μονοκλωνικο αντισωμα και χρησεις αυτου |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |